|
|
|
 Pharmacokinetic research
Singh K, Dickinson L, Chaikan A, Back D, Fletcher C, Pozniak A, Moyle G, Nelson M, Gazzard B, Herath D, Boffito M.
Pharmacokinetics and Safety of Saquinavir/Ritonavir and Omeprazole in HIV-infected Subjects.
Clin Pharmacol Ther. 2007 Sep 26; [Epub ahead of print]
PMID: 17898705 [PubMed - as supplied by publisher]
Waters LJ, Moyle G, Bonora S, D'Avolio A, Else L, Mandalia S, Pozniak A, Nelson M, Gazzard B, Back D, Boffito M.
Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients.
Antivir Ther. 2007;12(5):825-30.
PMID: 17713166 [PubMed - indexed for MEDLINE]
Boffito M, Winston A, Jackson A, Fletcher C, Pozniak A, Nelson M, Moyle G, Tolowinska I, Hoetelmans R, Miralles D, Gazzard B.
Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance.
AIDS. 2007 Jul 11;21(11):1449-55.
PMID: 17589191 [PubMed - indexed for MEDLINE]
Dickinson L, Back D, Pozniak A, Khoo S, Boffito M.
Limited-sampling strategy for the prediction of boosted hard-gel saquinavir exposure at a dosage of 1000/100 mg twice daily in human immunodeficiency virus-infected individuals.
Ther Drug Monit. 2007 Jun;29(3):361-7.
Ford J, Boffito M, Maitland D, Hill A, Back D, Khoo S, Nelson M, Moyle G, Gazzard B, Pozniak A.
Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients.
J Antimicrob Chemother. 2006 Nov;58(5):1009-16. Epub 2006 Sep 19.
PMID: 16984898 [PubMed - indexed for MEDLINE]
Boffito M, Maitland D, Dickinson L, Back D, Hill A, Fletcher C, Moyle G, Nelson M, Gazzard B, Pozniak A.
Pharmacokinetics of saquinavir hard-gel/ritonavir and atazanavir when combined once daily in HIV Type 1-infected individuals administered different atazanavir doses.
AIDS Res Hum Retroviruses. 2006 Aug;22(8):749-56.
PMID: 16910830 [PubMed - indexed for MEDLINE]
Winston A, Patel N, Back D, Khoo S, Bulbeck S, Mandalia S, Pozniak AL, Nelson M, Moyle G, Gazzard B, Boffito M.
Different methods to calculate the inhibitory quotient of boosted single protease inhibitors and their association with virological response.
J Acquir Immune Defic Syndr. 2006 Apr 15;41(5):675-6. No abstract available.
PMID: 16652044 [PubMed - indexed for MEDLINE]
Winston A, Back D, Fletcher C, Robinson L, Unsworth J, Tolowinska I, Schutz M, Pozniak AL, Gazzard B, Boffito M.
Effect of omeprazole on the pharmacokinetics of saquinavir-500 mg formulation with ritonavir in healthy male and female volunteers.
AIDS. 2006 Jun 26;20(10):1401-6.
PMID: 16791014 [PubMed - indexed for MEDLINE]
Boffito M, Maitland D, Dickinson L, Back D, Hill A, Fletcher C, Moyle G, Nelson M, Gazzard B, Pozniak A.
Boosted saquinavir hard gel formulation exposure in HIV-infected subjects: ritonavir 100 mg once daily versus twice daily.
J Antimicrob Chemother. 2005 Apr;55(4):542-5. Epub 2005 Feb 18.
PMID: 15722388 [PubMed - indexed for MEDLINE]
Boffito M, Back D, Stainsby-Tron M, Hill A, Di Perri G, Moyle G, Nelson M, Tomkins J, Gazzard B, Pozniak A.
Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered with tenofovir diproxil fumarate in HIV-1-infected subjects.
Br J Clin Pharmacol. 2005 Jan;59(1):38-42.
PMID: 15606438 [PubMed - indexed for MEDLINE
Boffito M, Pozniak A, Kearney BP, Higgs C, Mathias A, Zhong L, Shah J.
Lack of pharmacokinetic drug interaction between tenofovir disoproxil fumarate and nelfinavir mesylate.
Antimicrob Agents Chemother. 2005 Oct;49(10):4386-9.
PMID: 16189129 [PubMed - indexed for MEDLINE |
|
|
